OpenAI researcher's $2bn drug-discovery bet carries an India signal
An OpenAI scientist is leaving to build a $2bn AI drug-discovery startup, and its focus on repurposing old drugs is India's home turf. Here is why that matters.
The News
Barely two years after joining OpenAI, one of its scientists is stepping out on his own, and investors are already circling with a nine-figure cheque.
Miles Wang, a researcher who worked on OpenAI's efforts to apply machine learning to biology and the sciences, is preparing to leave the company to build his own drug-discovery venture. According to reporting by TechCrunch, Wang is in talks to raise 200 million dollars at a valuation of 2 billion dollars, with the venture firm Lightspeed lined up as the prospective lead investor. The conversations are still live and the figures could shift before anything is signed. Wang himself disputed the numbers and the description of the company, though he did not offer alternatives.
Wang joined OpenAI in 2024 after dropping out of Harvard's computer science degree, and several lab colleagues are expected to follow him. The new company is reported to be building AI models for drug discovery, with an early emphasis on finding fresh uses for medicines already approved by the US Food and Drug Administration, plus compounds that stumbled in past clinical trials. That repurposing route tends to reach revenue far quicker than inventing a molecule from scratch.
Why It Matters
The launch lands in the middle of a heavy capital cycle for computational biology. The same reporting pointed to Chai Discovery, which raised 400 million dollars at a 3.8 billion dollar valuation, and to Isomorphic Labs, the Alphabet spinout that closed a 2.1 billion dollar Series B in May 2026. Chai's co-founder Josh Meier is himself a former OpenAI staffer, underlining how quickly frontier-lab talent is being pulled toward the wet-lab economy.
The pattern rhymes with an earlier turning point. When DeepMind released AlphaFold2 in 2021 and opened up its predicted protein structures, it convinced a generation of investors that machine learning could compress the slowest, most expensive stage of pharmaceutical research. Today's billion-dollar valuations are the financial echo of that belief, now attached to founders who cut their teeth on large language models. The risk, as ever, is that the money is running ahead of a single approved drug reaching a patient.
Indian Angle
For India, the strategy on display matters more than the headline valuation. Repurposing approved and shelved drugs is exactly the terrain where Indian pharmaceutical companies already lead. India supplies a large share of the world's generic medicines, and firms such as Sun Pharma, Dr Reddy's Laboratories and Cipla hold deep libraries of off-patent molecules and manufacturing scale that an AI-first discovery layer could sharpen rather than replace.
There is a home-grown competitive angle too. Indian AI-in-biology startups such as Aganitha and Innoplexus, and contract-research players like Biocon's Syngene, chase overlapping ground at a fraction of Western cost. A 2 billion dollar valuation at the seed stage would be almost unthinkable for an Indian equivalent, which raises the question of whether domestic founders and investors are pricing the same opportunity too conservatively. For regulators at the CDSCO, a rise in AI-suggested repurposing candidates will eventually test how fast Indian trial approvals can move.
FAQ
Is the funding deal final?
No. The reported 200 million dollar raise at a 2 billion dollar valuation is still in discussion, with Lightspeed named as the likely lead investor. Miles Wang disputed the figures and the company description without giving alternatives, so the terms could change before anything is signed.
What will the startup actually build?
It is reported to be developing AI models for drug discovery, with an early focus on repurposing medicines already cleared by the US FDA and compounds that failed earlier clinical trials. Reusing known molecules can generate revenue faster than designing a new drug from the ground up.
Why does this matter for Indian pharma?
Drug repurposing is a core strength of Indian generics leaders such as Sun Pharma, Dr Reddy's and Cipla. An AI discovery layer that surfaces new uses for off-patent drugs could complement India's manufacturing scale, while also pressuring domestic biotech startups to raise their own ambitions and valuations.
Where can I read the original announcement?
The story was first reported by TechCrunch on 14 July 2026. The full original coverage, including the sourcing on Lightspeed and the comparison rounds, is linked in the attribution paragraph below.
This story was reported by TechCrunch. Read the full original coverage at TechCrunch.